Gent, Belgium, December 8, 2020 – OHMX.bio, a provider of cutting-edge “omics” solutions, and Fujirebio Europe announced today that they have been awarded a 720K EURO research grant from Flanders Innovation & Entrepreneurship (VLAIO) to develop a clinical in vitro diagnostics (IVD) platform incorporating third generation sequencing (TGS) technologies. The project, called IVD-seq, will initially focus on a cost-efficient, accurate and portable IVD modular solution for highly polymorphic regions. The partners aim to expand the resulting platform solution to other molecular diagnostic markers.
